Last reviewed 2026-04-23 · How we verify

Hi-dose iv MgSO4

High-dose intravenous magnesium sulfate acts as a neuroprotective agent and anticonvulsant by blocking N-methyl-D-aspartate (NMDA) receptors and stabilizing neuronal membranes.

High-dose intravenous magnesium sulfate acts as a neuroprotective agent and anticonvulsant by blocking N-methyl-D-aspartate (NMDA) receptors and stabilizing neuronal membranes. Used for Neuroprotection in acute ischemic stroke, Seizure prophylaxis in eclampsia/preeclampsia, Traumatic brain injury neuroprotection.

At a glance

Mechanism of action

Magnesium sulfate functions as a non-competitive antagonist at NMDA receptors, reducing excitotoxic calcium influx into neurons. It also stabilizes cell membranes and modulates neurotransmitter release, providing neuroprotection in acute neurological conditions. The high-dose intravenous formulation allows rapid achievement of therapeutic concentrations in the central nervous system.

Approved indications

• Neuroprotection in acute ischemic stroke
• Seizure prophylaxis in eclampsia/preeclampsia
• Traumatic brain injury neuroprotection

Common side effects

• Flushing
• Hypotension
• Hypermagnesemia
• Muscle weakness
• Respiratory depression

Key clinical trials

• Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Hi-dose iv MgSO4 CI brief — competitive landscape report
• Hi-dose iv MgSO4 updates RSS · CI watch RSS
• Hamad Medical Corporation portfolio CI